BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 26, 2005
 |  BioCentury  |  Emerging Company Profile

Elusys: Double-barreled antibodies

Elusys Therapeutics Inc. is building its hopes on a revenue stream from its Anthim monoclonal antibody against anthrax, which should be ready for government procurement by the middle of next year. The company plans to use the money to fund development of its preclinical pipeline of heteropolymer antibody candidates. In two years, Elusys plans to start clinical testing with the first of these anti-infective agents, which has shown potential both for treatment and prophylactic use in Staphylococcus aureus infections.

Anthim, a MAb against the Bacillus anthracis protective antigen, is designed to prevent the anthrax toxin from entering susceptible cells. Anthim was developed under a CRADA with the U.S. Army Medical Research Institute of Infectious Diseases.

Read the full 562 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >